Mutagenic Effects of Ribavirin on Hepatitis E Virus—Viral Extinction versus Selection of Fitness-Enhancing Mutations

Hepatitis E virus (HEV), an important agent of viral hepatitis worldwide, can cause severe courses of infection in pregnant women and immunosuppressed patients. To date, HEV infections can only be treated with ribavirin (RBV). Major drawbacks of this therapy are that RBV is not approved for administration to pregnant women and that the virus can acquire mutations, which render the intra-host population less sensitive or even resistant to RBV. One of the proposed modes of action of RBV is a direct mutagenic effect on viral genomes, inducing mismatches and subsequent nucleotide substitutions. These transition events can drive the already error-prone viral replication beyond an error threshold, causing viral population extinction. In contrast, the expanded heterogeneous viral population can facilitate selection of mutant viruses with enhanced replication fitness. Emergence of these mutant viruses can lead to therapeutic failure. Consequently, the onset of RBV treatment in chronically HEV-infected individuals can result in two divergent outcomes: viral extinction versus selection of fitness-enhanced viruses. Following an overview of RNA viruses treated with RBV in clinics and a summary of the different antiviral modes of action of this drug, we focus on the mutagenic effect of RBV on HEV intrahost populations, and how HEV is able to overcome lethal mutagenesis.

[1]  N. Kamar,et al.  Treatment of hepatitis E virus , 2016, Current opinion in infectious diseases.

[2]  X. de Lamballerie,et al.  Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. , 2016, Journal of hepatology.

[3]  M. B. Pisano,et al.  Corrigendum to "Hepatitis E virus infection in the HIV-positive patient" [J. Clin. Virol. 80 (2016) 102-106]. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[4]  T. Kuntzer,et al.  Hepatitis E virus infection as a direct cause of neuralgic amyotrophy , 2016, Muscle & nerve.

[5]  J. Izopet,et al.  Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis , 2016, Viruses.

[6]  M. B. Pisano,et al.  Hepatitis E virus infection in the HIV-positive patient. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  J. Neyts,et al.  Update on hepatitis E virology: Implications for clinical practice. , 2016, Journal of hepatology.

[8]  J. Neyts,et al.  Extra‐hepatic replication and infection of hepatitis E virus in neuronal‐derived cells , 2016, Journal of viral hepatitis.

[9]  Guangdi Li,et al.  Approved Antiviral Drugs over the Past 50 Years , 2016, Clinical Microbiology Reviews.

[10]  R. Shi,et al.  Evidence of Hepatitis E virus breaking through the blood–brain barrier and replicating in the central nervous system , 2016, Journal of viral hepatitis.

[11]  M. Manns,et al.  In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome , 2016, Gut.

[12]  H. Blum History and Global Burden of Viral Hepatitis , 2016, Digestive Diseases.

[13]  M. Peppelenbosch,et al.  Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection , 2016, Journal of viral hepatitis.

[14]  P. Cintas,et al.  Hepatitis E virus and neurological injury , 2016, Nature Reviews Neurology.

[15]  T. Pietschmann,et al.  Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication , 2016, Antimicrobial Agents and Chemotherapy.

[16]  J. Izopet,et al.  Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy , 2015, Antimicrobial Agents and Chemotherapy.

[17]  E. Domingo,et al.  Antiviral Strategies Based on Lethal Mutagenesis and Error Threshold. , 2015, Current topics in microbiology and immunology.

[18]  J. C. Nuño,et al.  Theories of Lethal Mutagenesis: From Error Catastrophe to Lethal Defection. , 2015, Current topics in microbiology and immunology.

[19]  P. Schuster,et al.  What Is a Quasispecies? Historical Origins and Current Scope. , 2015, Current topics in microbiology and immunology.

[20]  P. Couzigou,et al.  Neurologic Disorders in Immunocompetent Patients with Autochthonous Acute Hepatitis E , 2015, Emerging infectious diseases.

[21]  J. Prpić,et al.  The application of single strand conformation polymorphism (SSCP) analysis in determining Hepatitis E virus intra-host diversity. , 2015, Journal of virological methods.

[22]  F. Negro,et al.  Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes , 2015, Gut.

[23]  O. Ramilo,et al.  New options in the treatment of respiratory syncytial virus disease. , 2015, The Journal of infection.

[24]  M. Manns,et al.  The impact of hepatitis E in the liver transplant setting. , 2014, Journal of hepatology.

[25]  M. Manns,et al.  A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. , 2014, Gastroenterology.

[26]  M. Manns,et al.  Hepatitis E in Germany--an under-reported infectious disease. , 2014, Deutsches Arzteblatt international.

[27]  P. Simmonds,et al.  Consensus proposals for classification of the family Hepeviridae , 2014, The Journal of general virology.

[28]  H. Dalton,et al.  Guillain-Barré syndrome associated with preceding hepatitis E virus infection , 2014, Neurology.

[29]  R. Viswanathan Infectious hepatitis in Delhi (1955-56): a critical study-epidemiology. 1957. , 2013, The National medical journal of India.

[30]  S. Emerson,et al.  Ribavirin Inhibits In Vitro Hepatitis E Virus Replication through Depletion of Cellular GTP Pools and Is Moderately Synergistic with Alpha Interferon , 2013, Antimicrobial Agents and Chemotherapy.

[31]  J. Neyts,et al.  Intervention strategies for emerging viruses: use of antivirals , 2013, Current Opinion in Virology.

[32]  A. Perelson,et al.  Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C , 2013, Gut.

[33]  Kenneth A. Johnson,et al.  NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent RNA polymerase , 2013, Proceedings of the National Academy of Sciences.

[34]  T. Liang,et al.  The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C , 2012, Antiviral chemistry & chemotherapy.

[35]  M. Denison,et al.  Implications of altered replication fidelity on the evolution and pathogenesis of coronaviruses , 2012, Current Opinion in Virology.

[36]  L. Rostaing,et al.  Hepatitis E Virus Quasispecies and the Outcome of Acute Hepatitis E in Solid-Organ Transplant Patients , 2012, Journal of Virology.

[37]  E. Domingo,et al.  Viral Quasispecies Evolution , 2012, Microbiology and Molecular Reviews.

[38]  M. Manns,et al.  Pathogenesis and treatment of hepatitis e virus infection. , 2012, Gastroenterology.

[39]  Y. Hiasa,et al.  Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8. , 2012, The Journal of infectious diseases.

[40]  Suresh Mahalingam,et al.  Chikungunya: a re-emerging virus , 2012, The Lancet.

[41]  J. Neyts,et al.  Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. , 2011, Current opinion in virology.

[42]  D. Feigelstock,et al.  Selection of hepatitis C virus resistant to ribavirin , 2011, Virology Journal.

[43]  S. Günther,et al.  Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. , 2011, Antiviral research.

[44]  S. Panda,et al.  Hepatitis E virus replication involves alternating negative- and positive-sense RNA synthesis. , 2011, The Journal of general virology.

[45]  E. Domingo,et al.  A Multi-Step Process of Viral Adaptation to a Mutagenic Nucleoside Analogue by Modulation of Transition Types Leads to Extinction-Escape , 2010, PLoS pathogens.

[46]  Edward C Holmes,et al.  The RNA virus quasispecies: fact or fiction? , 2010, Journal of molecular biology.

[47]  J. Hoofnagle,et al.  Ribavirin improves early responses to peginterferon through improved interferon signaling. , 2010, Gastroenterology.

[48]  R. Porte,et al.  Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha‐2b , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[49]  L. Rostaing,et al.  Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  M. Manns,et al.  Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[51]  E. Domingo,et al.  Potential Benefits of Sequential Inhibitor-Mutagen Treatments of RNA Virus Infections , 2009, PLoS pathogens.

[52]  M. Lai,et al.  Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities , 2009, FEBS letters.

[53]  M. Eigen,et al.  The Hypercycle: A principle of natural self-organization , 2009 .

[54]  E. Domingo,et al.  Counteracting Quasispecies Adaptability: Extinction of a Ribavirin-Resistant Virus Mutant by an Alternative Mutagenic Treatment , 2009, PloS one.

[55]  G. Moonen,et al.  Guillain-Barré syndrome following hepatitis E. , 2009, World journal of gastroenterology.

[56]  C. Roth,et al.  New opportunities for field research on the pathogenesis and treatment of Lassa fever. , 2008, Antiviral research.

[57]  J. Hoofnagle,et al.  Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop , 2007, Hepatology.

[58]  M. Cam,et al.  Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response , 2007, Hepatology.

[59]  J. Deval,et al.  Pyrophosphorolytic Excision of Nonobligate Chain Terminators by Hepatitis C Virus NS5B Polymerase , 2007, Antimicrobial Agents and Chemotherapy.

[60]  R. Sidwell,et al.  Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. , 2007, Antiviral research.

[61]  E. Domingo,et al.  Foot-and-Mouth Disease Virus Mutant with Decreased Sensitivity to Ribavirin: Implications for Error Catastrophe , 2006, Journal of Virology.

[62]  C. Jonsson,et al.  Activity of Ribavirin against Hantaan Virus Correlates with Production of Ribavirin-5′-Triphosphate, Not with Inhibition of IMP Dehydrogenase , 2006, Antimicrobial Agents and Chemotherapy.

[63]  K. Gutkowski,et al.  [Viral hepatitis during pregnancy]. , 2006, Ginekologia polska.

[64]  Alexander E Gorbalenya,et al.  Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[65]  M. Vignuzzi,et al.  Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population , 2006, Nature.

[66]  C. Cameron,et al.  Mechanisms of action of ribavirin against distinct viruses , 2005, Reviews in medical virology.

[67]  L. Beeren,et al.  The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro. , 2005, RNA.

[68]  J. Pelletier,et al.  Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. , 2005, RNA.

[69]  N. Pariente,et al.  Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus. , 2005, Virus research.

[70]  E. De Clercq,et al.  The Predominant Mechanism by Which Ribavirin Exerts Its Antiviral Activity In Vitro against Flaviviruses and Paramyxoviruses Is Mediated by Inhibition of IMP Dehydrogenase , 2005, Journal of Virology.

[71]  Marco Vignuzzi,et al.  Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. , 2005, Virus research.

[72]  M. Siriwardana,et al.  Evidence for hepatitis E virus quasispecies. , 2004, The Journal of general virology.

[73]  Jean-Louis Romette,et al.  A Structural Basis for the Inhibition of the NS5 Dengue Virus mRNA 2′-O-Methyltransferase Domain by Ribavirin 5′-Triphosphate* , 2004, Journal of Biological Chemistry.

[74]  A. Amoroso,et al.  The role of ribavirin in the combination therapy of hepatitis C virus infection. , 2004, Current pharmaceutical design.

[75]  Isabelle Bougie,et al.  The Broad Spectrum Antiviral Nucleoside Ribavirin as a Substrate for a Viral RNA Capping Enzyme* , 2004, Journal of Biological Chemistry.

[76]  A. Neumann,et al.  Antiviral action of ribavirin in chronic hepatitis C. , 2004, Gastroenterology.

[77]  S. Briolant,et al.  In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. , 2004, Antiviral research.

[78]  E. Domingo,et al.  Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. , 2003, Virology.

[79]  J. Pawlotsky,et al.  Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. , 2003, Antiviral research.

[80]  Julie K. Pfeiffer,et al.  A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[81]  R. Garofalo,et al.  Ribavirin Treatment Up-Regulates Antiviral Gene Expression via the Interferon-Stimulated Response Element in Respiratory Syncytial Virus-Infected Epithelial Cells , 2003, Journal of Virology.

[82]  Natale Scaramozzino,et al.  Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. , 2003, Antiviral research.

[83]  William E. Severson,et al.  Ribavirin Causes Error Catastrophe during Hantaan Virus Replication , 2003, Journal of Virology.

[84]  E. Schmidt,et al.  Viral RNA Mutations Are Region Specific and Increased by Ribavirin in a Full-Length Hepatitis C Virus Replication System , 2002, Journal of Virology.

[85]  Z. Hong,et al.  Mechanism of action of ribavirin in the combination treatment of chronic HCV infection , 2002, Hepatology.

[86]  R. Lanford,et al.  Ribavirin Induces Error-Prone Replication of GB Virus B in Primary Tamarin Hepatocytes , 2001, Journal of Virology.

[87]  N. Snell Ribavirin - current status of a broad spectrum antiviral agent , 2001, Expert opinion on pharmacotherapy.

[88]  S. Goodman,et al.  Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. , 2001, JAMA.

[89]  J. Arnold,et al.  The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen , 2000, Nature Medicine.

[90]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[91]  O. Weiland,et al.  The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. , 1998, The Journal of general virology.

[92]  V. Khoshoo,et al.  Reduced long‐term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: A preliminary report , 1998, Pediatric pulmonology.

[93]  G. Lemay,et al.  Viral and cellular enzymes involved in synthesis of mRNA cap structure. , 1997, Virology.

[94]  P. D. Nagy,et al.  A novel 3'-end repair mechanism in an RNA virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[95]  M A Nowak,et al.  Viral dynamics in hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[96]  T. Mosmann,et al.  The expanding universe of T-cell subsets: Th1, Th2 and more. , 1996, Immunology today.

[97]  E. De Clercq,et al.  Molecular approaches for the treatment of hemorrhagic fever virus infections. , 1993, Antiviral research.

[98]  A. W. Tam,et al.  Hepatitis E virus (HEV): The novel agent responsible for enterically transmitted non-A, non-B hepatitis , 1991, Gastroenterologia Japonica.

[99]  J. Huggins Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. , 1989, Reviews of infectious diseases.

[100]  K. O'connell,et al.  Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription , 1988, Antimicrobial Agents and Chemotherapy.

[101]  F. Hayden,et al.  Oral ribavirin treatment of influenza A and B , 1987, Antimicrobial Agents and Chemotherapy.

[102]  V. Stollar,et al.  Sindbis virus mutants resistant to mycophenolic acid and ribavirin. , 1987, Virology.

[103]  V. Knight,et al.  Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. , 1985, Antiviral research.

[104]  E. Domingo,et al.  Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. , 1983, Virology.

[105]  J. Holland,et al.  High multiplicities of infection favor rapid and random evolution of vesicular stomatitis virus. , 1982, Virology.

[106]  Katherine Spindler,et al.  Rapid evolution of RNA genomes. , 1982, Science.

[107]  R. Couch,et al.  RIBAVIRIN SMALL-PARTICLE AEROSOL TREATMENT OF INFLUENZA , 1981, The Lancet.

[108]  D. Alling,et al.  Lack of Interference of Guanosine with Ribavirin Aerosol Treatment of Influenza A Infection in Mice , 1981, Antimicrobial Agents and Chemotherapy.

[109]  S. Skidmore,et al.  Incidence and severity of viral hepatitis in pregnancy. , 1981, The American journal of medicine.

[110]  E. Domingo,et al.  Nucleotide sequence heterogeneity of the RNA from a natural population of foot-and-mouth-disease virus. , 1980, Gene.

[111]  R. Smith,et al.  The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. , 1979, Biochemical and biophysical research communications.

[112]  T. Zimmerman,et al.  Metabolism of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5'-triphosphates in human blood and L5178Y cells. , 1978, Biochemical pharmacology.

[113]  M. Eigen,et al.  The hypercycle. A principle of natural self-organization. Part A: Emergence of the hypercycle. , 1977, Die Naturwissenschaften.

[114]  L. Philipson,et al.  Inhibition of Influenza Virus Ribonucleic Acid Polymerase by Ribavirin Triphosphate , 1977, Antimicrobial Agents and Chemotherapy.

[115]  W. Müller,et al.  Virazole (1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide; A cytostatic agent , 1977 .

[116]  R. J. Bauer,et al.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[117]  R. K. Robins,et al.  Broad-Spectrum Antiviral Activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamide , 1972, Science.

[118]  L. Sexton The Treatment of Yellow Fever , 1903, The Indian medical gazette.

[119]  G. Marano,et al.  Hepatitis E: an old infection with new implications. , 2015, Blood transfusion = Trasfusione del sangue.

[120]  V. Mishra,et al.  Viral Hepatitis in Pregnancy--A study of its Effect on Maternal and Foetal Outcome. , 2015, The Journal of the Association of Physicians of India.

[121]  A. Randolph,et al.  Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. , 2004, The Cochrane database of systematic reviews.

[122]  A S Perelson,et al.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.

[123]  E. Domingo,et al.  RNA virus mutations and fitness for survival. , 1997, Annual review of microbiology.

[124]  J. B. Antczak,et al.  Studies on the mechanism of the antiviral activity of ribavirin against reovirus. , 1989, Virology.

[125]  J. McCormick,et al.  Lassa fever. Effective therapy with ribavirin. , 1986, The New England journal of medicine.

[126]  W. Müller,et al.  Virazole (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; a cytostatic agent. , 1977, Biochemical pharmacology.